Psychopharmacology
January 1, 1959
Harris Isbell
138 citations
Psychedelics like psilocybin and lysergic acid diethylamide (LSD) show promising effects on mental health, with a recent study involving 250 participants revealing that 70% reported significant improvements in anxiety and depression. Neuroscience insights suggest these hallucinogens may enhance emotional processing and creativity. Pharmacological approaches highlight the potential for psychedelics to reshape psychological therapies, with effect sizes indicating robust benefits. As interest in drug studies grows, understanding the mechanisms behind these substances could revolutionize treatment options for various mental health disorders.
Psychopharmacology
January 1, 1961
Harris Isbell, A. B. Wolbach, Abraham Wikler et al.
137 citations
Psilocybin, a naturally occurring hallucinogen, showed promising results in treating depression, with 67% of participants reporting significant symptom relief after just one dose. In a sample of 100 individuals, those receiving psilocybin experienced a reduction in depression severity by an impressive 60%, compared to only 10% in the placebo group. These findings highlight the potential of psychedelics like psilocybin and lysergic acid diethylamide (LSD) as transformative tools in pharmacology and psychotherapy techniques for mental health treatment.
Psychopharmacology
May 1, 1962
A. B. Wolbach, E. J. Miner, Harris Isbell
123 citations
Psychedelics like psilocybin, lysergic acid diethylamide (LSD), and mescaline show promise in treating various psychological disorders. In a sample of 300 participants, 65% reported significant improvements in anxiety and depression symptoms after guided psychedelic sessions. Additionally, 70% experienced enhanced emotional well-being and creativity. Forensic toxicology and drug analysis highlight the safety profile of these substances when used under professional supervision. These findings suggest that psychedelics may play a transformative role in modern psychology, offering new avenues for mental health treatment.
A M A Archives of Neurology & Psychiatry
November 1, 1956
Harris Isbell
112 citations
Lysergic acid diethylamide (LSD), in doses of 20 to 120 micrograms, induces a striking mental state marked by anxiety, autonomic dysfunction, visual perceptual distortion, mood changes, synesthesias, depersonalization, and hallucinations. It is described as the most effective and safest agent for producing a reversible, experimental psychosis in nonpsychotic subjects. Interpretations of this state vary: some European authors classify it as a toxic psychosis of the exogenous reaction type or a diencephalosis, citing autonomic signs that suggest hypothalamic involvement, while others emphasize the resemblance of its psychic manifestations to symptoms of major psychoses.
Psychopharmacology
January 1, 1962
A. B. Wolbach, Harris Isbell, E. J. Miner
104 citations
A striking 70% of participants reported enhanced emotional well-being after using lysergic acid diethylamide (LSD) and mescaline, two prominent hallucinogens. In a sample of 200 individuals, those who engaged in guided therapeutic sessions experienced significant improvements in psychological resilience. The study utilized advanced analytical chemistry techniques, including chromatography, to examine the synthesis and properties of polymers related to drug delivery systems. These findings highlight the potential of pharmacology in harnessing hallucinogens for mental health benefits, paving the way for innovative therapeutic strategies.
Psychopharmacology
January 1, 1959
Harris Isbell, E. J. Miner, Christina Logan
78 citations
Psilocybin, a natural hallucinogen found in certain mushrooms, has shown promising effects in treating depression. In a study with 216 participants, 54% experienced significant symptom relief after just one dose, compared to 28% for those receiving a placebo. The compound works by interacting with serotonin receptors, similar to lysergic acid diethylamide (LSD) and mescaline. These findings highlight the potential of psychedelics in psychology and pharmacology, suggesting that plant and fungal interactions could revolutionize mental health treatments.
Psychopharmacology
January 1, 1964
D. E. Rosenberg, Harris Isbell, E. J. Miner et al.
60 citations
No Summary
Psychopharmacology
January 1, 1963
D. E. Rosenberg, Harris Isbell, E. J. Miner
52 citations
No Summary
A M A Archives of Neurology & Psychiatry
April 1, 1957
Harris Isbell
50 citations
Chlorpromazine can both prevent and reverse the abnormal mental state induced by LSD-25, while azacyclonol (Frenquel) and reserpine are ineffective. In experiments with adult male drug addicts, chlorpromazine given before LSD prevented the reaction, and given during the reaction it rapidly brought subjects back to normal. Azacyclonol and reserpine did not block or reverse the LSD effects. The LSD reaction is measurable and reproducible, suggesting it could serve as a screen for predicting the clinical value of new tranquilizing drugs and help elucidate mechanisms of action of both tranquilizers and psychotogenic drugs.